echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Memantine Hydrochloride Sustained-Release Capsules, a subsidiary of Renfu Pharmaceutical Holdings Limited, obtained the drug registration certificate

    Memantine Hydrochloride Sustained-Release Capsules, a subsidiary of Renfu Pharmaceutical Holdings Limited, obtained the drug registration certificate

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 14, Renfu Pharmaceutical announced that its holding subsidiary, Yichang Renfu, has recently received the "Drug Registration Certificate" for Memantine Hydrochloride Sustained-Release Capsules approved and issued by the State Drug Administration for the treatment of moderate to severe cases.


    Yichang Renfu's Memantine Hydrochloride Sustained-Release Capsules was approved by the FDA in April 2021, and the registration application for the drug was submitted to the State Drug Administration in April 2020 and was accepted.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.